The 2026 oral probiotic and topical secretome trial will not change acne care yet because it has no results to use. It describes a research plan, not proof that these add-ons clear acne.
Oral probiotics here mean live bacteria taken by mouth. Topical secretome means a mixture of substances released by cells, applied to skin. BMJ Open published the phase 2 double-blind randomised controlled trial protocol on 4 June 2026 for acne vulgaris restoration, according to the trial protocol.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What will researchers actually test?
- Why are size and length limits important?
- How does this fit current acne treatment?
- What should people with acne-prone skin do now?
What will researchers actually test?
The plan enrolls 64 patients with mild-to-moderate acne. Each person receives standard therapy plus either active or placebo oral probiotics and either active or placebo topical secretome, creating four groups, as listed in the trial listing. Treatment lasts 8 weeks.
Researchers will count comedones and inflammatory lesions with Yolov8 image analysis. They will also track acne severity, faecal and skin microbiome, IL-6 and tryptophan metabolites. This design can separate the effect of each add-on. It can also show whether the combination works better than either part alone.
Why are size and length limits important?
Sixty-four patients is a small study. The authors state this sample may limit power to detect smaller effects across outcome measures. Eight weeks is also short for acne.
The authors state this period cannot capture long-term sustainability or relapse rates. That matters because acne often returns after treatment stops. A brief improvement may fade without longer follow-up.
How does this fit current acne treatment?
Current U.S. acne guidance centers on proven drugs. The American Academy of Dermatology strongly recommends benzoyl peroxide, topical retinoids such as adapalene, tretinoin, tazarotene and trifarotene, oral doxycycline, topical antibiotics and combinations, as reported in the updated acne guidelines.
Those guidelines do not include oral probiotics or secretome. Doctors prescribe them because large trials show they reduce lesions and prevent new ones. A small exploratory protocol cannot replace that evidence base. At most, it can justify a larger, longer trial.
What should people with acne-prone skin do now?
Keep using treatments with strong evidence first. Do not pay extra for probiotic or secretome acne products based on this protocol alone.
Caution is especially important for cell-derived skin products. The FDA states there are currently no FDA-approved exosome products and warns about clinics marketing unapproved regenerative products with unsubstantiated claims, according to the consumer alert on regenerative products.
- Continue benzoyl peroxide, retinoid, antibiotic or doxycycline treatment as prescribed
- Ask a dermatologist before adding an oral probiotic supplement
- Be cautious about clinics selling exosome or regenerative skin cures
- Track breakouts, irritation and missed doses for 8 to 12 weeks before judging progress
You Might Also Like
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Why the Findings May Not Change Acne Care Yet for People With Acne-Prone Skin
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: Why the Findings May Not Change Acne Care Yet for People With Acne-Prone Skin
- The 2026 Global Delphi Consensus on Acne and the Microbiome: Safety and Skin-Reaction Questions for People With Acne-Prone Skin